同仁堂医养则于近日第三次向港交所递交招股书。同仁堂医养为同仁堂集团旗下二级集团。招股书显 示，在上市前的股东架构中，同仁堂直接持股83.98%，间接通过同仁堂康养、同仁堂传承基金管理、 同仁堂医疗基金管理等，合计行使93.83%的投票权。根据弗若斯特沙利文报告，按2024年总门诊人次 及住院人次计， 同仁堂医养是中国非公立中医院医疗服务行业中最大的中医院集团，市场份额为 1.7%；同期按总收入计，同仁堂医养在非公立中医院医疗服务行业排名第二，市场份额为0.2%，其市 场规模占同年中国中医院医疗服务行业总规模的46.5%。 随着A股公司掀起港股上市的热潮，A股上市公司分拆子公司赴港上市（"A拆H"）呈现明显升温态势。 多家公司启动"A拆H" 近期，潍柴动力分拆的潍柴雷沃、同仁堂分拆的同仁堂医养、紫金矿业旗下紫金黄金国际向港交所主板 递表，此前，歌尔股份分拆的歌尔微、诺力股份分拆的中鼎智能已在冲刺港股上市，美的集团也公布拟 将安得智联分拆的目标上市板块调整为港交所主板，南方航空也被传或考虑分拆南航物流在港上市。而 分拆自南山铝业的南山铝业国际、分拆自科大讯飞的讯飞医疗科技则已登陆港股市场。这些公司涵盖医 药、制造 ...

Core Viewpoint - Beijing Tongrentang Medical Investment Co., Ltd. (Tongrentang Medical) has submitted its IPO application for the third time in a year, aiming to become the fourth listed company under the Tongrentang Group, which includes Tongrentang, Tongrentang Technology, and Tongrentang Guoyao [1][8] Company Overview - Tongrentang Medical, established in 2015, is the largest private traditional Chinese medicine hospital group in China, holding a market share of 1.7% in terms of outpatient and inpatient visits in 2024 [1] - The company ranks second in the private traditional Chinese medicine medical service industry with a market share of 0.2% in total medical service revenue, accounting for 46.5% of the market size of the traditional Chinese medicine medical service industry in China [1] Financial Performance - Revenue from Tongrentang Medical has shown growth from approximately 911 million yuan in 2022 to 1.175 billion yuan in 2024, with net profits turning positive in 2022 after a series of acquisitions [3][4] - The company reported net profits of -9.23 million yuan in 2022, 42.63 million yuan in 2023, and 46.19 million yuan in 2024 [3] Acquisition Strategy - The company's growth has been primarily driven by acquisitions, with plans to acquire five profit-making medical institutions by the end of 2029, focusing on economically active regions such as Beijing and the Yangtze River Delta [5][8] - Tongrentang Medical has increased its total number of medical visits from 1.3 million in 2022 to 3 million in 2024, with a compound annual growth rate of 51.9% [4] Debt and Financial Risks - The company's debt ratio has risen significantly from less than 10% in 2021 to 45.2% in 2024, raising concerns about the sustainability of its growth [2][7] - As of April 30, 2024, the total outstanding bank loans amounted to 142 million yuan, with a significant portion of its equity pledged to secure financing [7] Market Position and Competition - The number of participants in China's private traditional Chinese medicine medical service industry has increased from 2,525 in 2019 to 3,614 in 2024, indicating intensified competition [9] - Despite the competitive landscape, Tongrentang Medical benefits from the strong brand recognition of the "Tongrentang" name and has a well-established business model that includes medical services, management services, and health product sales [9] IPO Objectives - The funds raised from the IPO are intended for expanding the company's medical service network, enhancing service capabilities, repaying bank loans, and general corporate purposes [8] - The repeated submissions of the IPO application may indicate challenges in meeting market expectations or regulatory requirements [8]